Latest Funding News

Pengana Capital Group reports a steady increase in Funds Under Management to $3.84 billion as of October 2025, with a significant $69.1 million capital raise set to boost figures in November.

Locksley Resources has partnered with Columbia University to develop cutting-edge, sustainable technologies for rare earth and critical mineral processing in the US, advancing its Mine-to-Market strategy amid growing government support.

Aurora Labs has entered a strategic MOU with Ares Armaments to co-develop advanced metal components for defence, aiming to revolutionise small-arms manufacturing with additive technology.

Island Pharmaceuticals has secured FDA confirmation that its antiviral Galidesivir can proceed under the Animal Rule pathway for Marburg virus, qualifying for a lucrative Priority Review Voucher. This regulatory milestone accelerates the drug’s path to approval and potential government stockpile inclusion.

Cann Group Limited reminds eligible shareholders that its Share Purchase Plan (SPP) closes today, offering new shares at a discount plus free attaching options, pending shareholder approval.

Algorae Pharmaceuticals has launched a Loyalty Options Offer, allowing eligible shareholders to purchase options at a nominal price, aiming to reward loyalty and support future growth funding.

HMC Capital has secured an increased and extended revolving debt facility, enhancing its underwriting capacity and supporting strategic growth initiatives, including its energy transition efforts.

IperionX rebuffs short seller claims by highlighting robust US government support and accelerating titanium production scale-up in Virginia. The company secures over $59 million in funding and advances critical minerals projects toward commercial readiness.

Syrah Resources has secured an $8.5 million tranche from its US DFC loan, deferred interest payments to mid-2026, and issued warrants to the DFC, reinforcing the strategic importance of its Balama graphite operation.

Algorae Pharmaceuticals has announced a non-renounceable Loyalty Options Offer to eligible shareholders, aiming to raise up to $337,678 before costs, with potential additional capital of $4.7 million if all options are exercised. The capital raise supports the company’s pharmaceutical and AI research and development ambitions.

Race Oncology has announced pivotal new clinical trials for its lead asset RC220, aiming to accelerate regulatory approval in Acute Myeloid Leukemia and tackle resistance in Non-Small Cell Lung Cancer.

Energy World Corporation Ltd has outlined a strategic reset including a $442 million debt-to-equity conversion and is progressing towards commissioning its flagship Pagbilao LNG and power project in the Philippines, alongside advancing its Sengkang LNG facility in Indonesia.